Director, Life Sciences Senior Analyst
Areas of focus: Life Sciences
In May 2020, Steve was selected as a senior analyst in RSM’s cutting edge Industry Eminence Program, which positions its senior analysts to understand, forecast and communicate economic, business and technology trends shaping the industries RSM serves. These senior analysts advise clients on conditions influencing middle market leaders. Steve’s focus is on the life sciences industry.
Summary of experience
Steve manages the Philadelphia market NetSuite team and provides NetSuite consulting services to a variety of clients in industries including life sciences, technology and wholesale distribution. Steve leads projects that require complex integrations, customizations and complex finance requirements.
As a member of RSM’s life sciences team, Steve consistently supports clients in the industry across the country. He also participates in the PACT MedTech series and is involved in multiple regional and national life sciences initiatives.
Steve has deep technical expertise and has a keen ability to work with people at all levels of a company. As ERP implementations involve staff with various backgrounds and expertise, Steve ensures that strategic insights from all levels are considered.
Prior to joining RSM, Steve spent three years managing the implementation of NetSuite for a rapidly growing multinational CRO and providing software and services for collecting patient reported outcomes in clinical trials. This implementation required skills related to finance (multiple currency, multiple subsidiary), logistics (managing hundreds of thousands of serialized devices distributed to over 100 countries), project accounting and project management, and CRM. Prior to this, Steve worked in a variety of technical and finance roles at a medical technology company.
- Master of Business Administration, University of Colorado - Boulder
- Bachelor of Science in Engineering, computer engineering, Case Western Reserve University
Cyberthreats are here to stay for life sciences companies, but staying a step ahead of the criminals can ensure the good guys win the day.
Middle market biopharma companies face business challenges as they expand and launch new products. What are these issues and opportunities?
THE REAL ECONOMY
Governments and businesses—including the middle market firms that constitute the real economy—will face new challenges.
Here are some areas in which CMOs, CROs and life sciences companies with established product pipelines might consider investing right now.
Biden plans to expand Medicare, a move that the Congressional Budget Office estimates would cut drug spending by $450 billion over 10 years.
With the election approaching, RSM is looking at the economic stakes and the key issues for the life sciences industry.
We suggest stress-testing your supply chain to determine what the actual or opportunity costs of disruption might be.
Whether developing drug therapies, designing medical devices, or more, life sciences companies have complex technology needs.
Life sciences companies are inherently fast-paced and back-office investments must evolve to match the changing needs of the organization.
More promise, more problems: Cyberattacks threaten life sciences companies researching COVID-19 vaccine.